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Abstract
Staphylococcus aureus, the leading cause of hospital-acquired infections in the United States, is also pathogenic to the
model nematode Caenorhabditis elegans. The C. elegans-S. aureus infection model was previously carried out on solid agar
plates where the bacteriovorous C. elegans feeds on a lawn of S. aureus. However, agar-based assays are not amenable to
large scale screens for antibacterial compounds. We have developed a high throughput liquid screening assay that uses
robotic instrumentation to dispense a precise amount of methicillin resistant S. aureus (MRSA) and worms in 384-well assay
plates, followed by automated microscopy and image analysis. In validation of the liquid assay, an MRSA cell wall defective
mutant, MW2DtarO, which is attenuated for killing in the agar-based assay, was found to be less virulent in the liquid assay.
This robust assay with a Z’-factor consistently greater than 0.5 was utilized to screen the Biomol 4 compound library
consisting of 640 small molecules with well characterized bioactivities. As proof of principle, 27 of the 30 clinically used
antibiotics present in the library conferred increased C. elegans survival and were identified as hits in the screen. Surprisingly,
the antihelminthic drug closantel was also identified as a hit in the screen. In further studies, we confirmed the anti-
staphylococcal activity of closantel against vancomycin-resistant S. aureus isolates and other Gram-positive bacteria. The
liquid C. elegans – S. aureus assay described here allows screening for anti-staphylococcal compounds that are not toxic to
the host.
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Introduction
Staphylococcus aureus is a human commensal that is a leading
cause of hospital and community-acquired infections [1,2],
including bacteremia and sepsis [3,4]. Staphylococci possess a
wide spectrum of virulence factors and have developed many
strategies to bypass host defense mechanisms [5,6]. In addition, the
rapid development of S. aureus strains resistant to b-lactam
antibiotics such as methicillin (MRSA) present challenges in the
treatment of staphylococcal infections. The CDC estimates that in
2011, MRSA was responsible for 80,461 life-threatening infections
in the United States alone [7]. In fact, the number of yearly deaths
from MRSA infection has surpassed that of AIDS [7]. These
statistics underscore the urgent need for novel anti-infectives
effective against S. aureus.
Traditional methods of antimicrobial drug discovery have
usually involved in vitro screening for antimicrobial activity and
then further in vitro/in vivo testing of the hits for toxicity followed
by Structure Activity Relationships (SAR) analysis [8]. One
shortcoming of this method of antibiotic discovery is that many
compounds that are lethal to bacteria are also toxic to humans.
We present here a model using a whole animal host Caenorhabditis
elegans for antimicrobial screening that enables simultaneous
assessment of the toxicity of the compound on the host as well
as the efficacy of the compound against the pathogen. In addition
to conventional antibiotics that affect bacterial growth or viability,
our whole animal screening model allows the identification of
immunomodulatory compounds and compounds that affect
pathogen virulence.
The free living nematode C. elegans has recently become a
popular model organism for studying pathogenesis of many
microbes [9,10], including S. aureus [11,12]. C. elegans growing on
a lawn of S. aureus die within five days, whereas nematodes feeding
on non-pathogenic E. coli, the normal laboratory food source, or
non-pathogenic Bacillus subtilis, live approximately 14 days [11,13].
Importantly, key virulence factors that are important for
staphylococcal pathogenesis in the nematode model are also
involved in pathogenesis in humans [11]. C. elegans are relatively
inexpensive to maintain and their use does not raise ethical
concerns related to the use of mammals in biological research. A
main objective of this study was to develop a C. elegans-MRSA
liquid infection assay for automated, high throughput screening of
small molecule libraries for antibacterial compounds. The
screening methodology was subsequently used to identify antimi-
crobials in the Biomol 4 library of FDA-approved drugs that
promote survival of infected worms. Proof of principle is
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demonstrated by the fact that out of the 30 clinically used
antibiotics represented in the library, 27 were identified as hits in
the screen (Tables 1 and 2). The method described here can be
applied to assays with other pathogens with only slight modifica-
tions. Our results confirm the utility of C. elegans as a screening
platform for antimicrobial drug discovery.
Materials and Methods
Bacterial and Nematode Strains
The S. aureus methicillin resistant strain MW2 BAA-1707
(ATCC, Manassas, VA, USA) was used throughout this study. It
is a community-acquired (CA-MRSA) strain, SCCmec Type IV,
Panton-Valentine Leucocidin (PVL)-Positive that was isolated in
1998 from a female patient in North Dakota (USA) [14]. The S.
aureus strain VRS1 carries a plasmid encoding the vanA gene that
confers resistance to vancomycin [15]. The cell wall defective
strain MW2DtarO expresses an inactive, truncated variant of TarO
containing only 80 aa [16]. Bacteria were grown at 37uC in tryptic
soy broth (TSB, Becton Dickinson and Company, NJ, USA).
The C. elegans glp-4(bn2);sek-1(km4) double mutant strain was
used throughout this study. Nematodes were maintained at 15uC
on a lawn of E. coli strain HB101 on 10 cm plates [17]. The glp-
4(bn2) mutation renders the strain incapable of producing progeny
at 25uC [18] and the sek-1(km4) mutation enhances sensitivity to
various pathogens [19], reducing assay time.
Compound Library
The Biomol 4 library (http://www.enzolifesciences.com/) is a
collection of 640 FDA-approved drugs that were chosen for their
chemical and pharmacological diversity. The library was obtained
from the Institute of Chemistry and Cell Biology (ICCB) at
Harvard Medical School in 384-well plates. For all plates, 0.1 ml of
each of the 2 mg/ml compound stocks in DMSO was pin
transferred to separate wells. The compounds were screened at a
final compound concentration of 2.86 mg/ml.
Z’-factor
Z’-factor is a measure of the quality of the HTS assay pipeline
and it is calculated from the positive and negative control data
[20]. Z’-factor = 1-((3sp +3sn)/|mp-mn|)) where sp and sn are the
standard deviations of the positive and negative controls respec-
tively and mp and mn are the means of the positive and negative
controls respectively. A Z’-factor .0.5 indicates a robust assay.
For experiments used to determine the Z’-factor of the assay, 1%
dimethyl sulfoxide (DMSO) was the negative control and
vancomycin hydrochloride (Sigma Aldrich, MO, USA) dissolved
in DMSO at a final concentration of 10 mg/ml was the positive
control.
Infection Assay for Compound Screen
S. aureus MW2 was grown overnight in TSB under aerobic
conditions with agitation at 37uC. To simulate the growth
environment of S. aureus in a wound abscess, the aerobic culture
was shifted to anaerobic growth conditions the next day by seeding
a 10 ml TSB culture tube with 100 ml of the aerobic culture,
sealing the tube in an air-tight manner, and incubating overnight
without agitation at 37uC. It has been shown that anaerobically
grown S. aureus exhibits a different pattern of virulence gene
expression than aerobically grown cultures [21]. Two thousand
glp-4(bn2);sek-1(km4) worms at the L1 stage were grown at 15uC on
SK agar plates with HB101 as the food source for four days until
the worms reached the gravid adult stage. Embryos were
harvested from adult worms according to a previously described
method [22] and the eggs were hatched by incubation in M9
buffer at 15uC for two days. Approximately 4,500 L1 hatchlings
were grown on SK-HB101 agar plates for 52 hours at the
restrictive temperature of 25uC until animals were sterile young
Table 1. Classes of compounds from the Biomol 4 library that
promote survival of nematodes infected with MRSA.
Category Number of hits
Antibiotics 27*
Anticancer 10
Antiviral 1
Antifungal 1
Antiarthritic drug 1
Non-steroidal estrogen 1
Antihelminth 1
Total 42 (6.6% hit rate)
*- Z scores.3 for 25 antibiotic hits and 2,Z score,3 for 2 antibiotic hits.
doi:10.1371/journal.pone.0089189.t001
Table 2. Antibiotic hits and their corresponding Z scores in
the C. elegans-MRSA infection assay.
Name Z score
Cefoperazone acid [39] 3.56
Cefotaxime acid [40] 6.44
Clinafloxacin HCl [41] 7.11
Clindamycin HCl [42] 23.82
Doxycycline HCl [43] 5.43
Enoxacin [44] 2.85
Enrofloxacin [45] 7.12
Fleroxacin [46] 3.51
Gatifloxacin [47] 6.73
Levofloxacin HCl [48] 7.16
Lincomycin [49] 21.13
Linezolid [42] 8.18
Lomefloxacin HCl [50] 7.11
Minocycline HCl [51] 5.18
Nadifloxacin [52] 6.68
Novobiocin Na [53] 30.07
Ofloxacin [54] 7.16
Pazufloxacin [55] 7.04
Pefloxacine mesylate [56] 7.16
Rifampicin [42] 29.85
Rifamycin sv [57] 7.12
Roxithromycin [58] 6.44
Rufloxacin [59] 2.01
Sarafloxacin HCl [54] 6.66
Sparfloxacin [60] 6.57
Tosufloxacin [61] 6.73
Troleandomycin [62] 23.10
doi:10.1371/journal.pone.0089189.t002
Whole Animal Drug Discovery against S. aureus
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e89189
adults. The worms were harvested by gently washing them off the
plates with M9 buffer.
The HTS assay was performed using 384-well plates (Corning
no. 3712). A Union Biometrica Complex Object Parametric
Analyzer and Sorter (COPASBioSort) was used to transfer 15
adult worms to each well of the assay plate. The total volume in
each well was 70 ml with the final composition being 70% M9
buffer, 19% Sheath solution (Union Biometrica Part no. 300-5101-
000), 10% TSB, and 1% DMSO or compounds dissolved in
DMSO. The bacterial concentration was adjusted to a final OD600
of 0.04. After 5 days of incubation in a humidified chamber at
25uC, the bacteria and other debris were washed from the wells
Figure 1. Flowchart representing the time line and work flow of the C. elegans-MRSA high throughput screening assay.
doi:10.1371/journal.pone.0089189.g001
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with a microplate washer, leaving 10 ml of assay volume with
worms following the final aspiration step. Finally, 60 ml of 0.9 mM
Sytox Orange in M9 was dispensed into each well for a final Sytox
concentration of 0.7 mM. The plates were incubated overnight at
25uC in a humidified chamber. The plates were imaged the next
day using an Image Xpress Micro automated microscope
(Molecular Devices), capturing both transmitted light and TRITC
(535 nm excitation, 610 nm emission) fluorescent images with a
2X objective.
Worm Survival Quantification using CellProfiler and Hit
Identification
The transmitted and fluorescent images of worms in 384 well
plates obtained using the Image Express Micro microscope were
processed with the open source image analysis software CellPro-
filer (http://www.cellprofiler.org/) using a pipeline of image
processing and analysis modules as described previously [23,24].
The ratio of Sytox worm area to bright field worm area, and the
resultant percentage survival data, is calculated by the software for
each well of the assay plates. In order to identify the hits, the Z
score was calculated from the ratio data. The Z score is defined as
Figure 2. Worm survival quantification using CellProfiler. Worms in 384-well plates were incubated with Sytox Orange, which specifically
stains dead worms. The results of several processing steps using CellProfiler are shown. The total area of fluorescent and bright field worms are
measured and worm survival in each well is calculated as a percentage. Top row: Raw fluorescent Sytox Orange and bright field images of an
untreated and an antibiotic-treated well. Middle row: Correction for uneven illumination of the bright field images. Cropping of Sytox images so
that total fluorescence measurements are only made within worm areas determined by the bright field images. Bottom row: Thresholding,
identifying worms and filtering for object size.
doi:10.1371/journal.pone.0089189.g002
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the number of standard deviations an observation is separated
from the mean; Z= (x2m)/s where x is the raw sample score, m is
the mean of the population and s is the standard deviation of the
population. Samples with Z.2s were considered as hits.
Antimicrobial Activity Testing
Compounds (10 mg/ml stock solution in DMSO) were tested
for antimicrobial activity by broth microdilution, adapted from
established protocols [25]. The assay was done in triplicate in 384-
well plates. The total volume in each well was 40 ml with the final
composition being 50% M9 buffer, 50% TSB. Two-fold serial
dilutions were carried out to get compounds in the concentration
range 0.78–50 mg/ml. The bacterial concentration was adjusted to
an initial OD600 of 0.03. After overnight incubation at 37uC, the
absorbance was measured to determine antimicrobial activity.
Results and Discussion
MRSA-C. elegans Liquid Killing Assay for High
Throughput Screening
C. elegans-S. aureus infection models have been used in several
studies investigating staphylococcal virulence and pathogenesis, as
well as in screens for compounds with antimicrobial activity
[11,12,26–30]. Previous work has demonstrated that S. aureus is
pathogenic to C. elegans and staphylococcal infection in nematodes
is characterized by bacterial accumulation that causes intestinal
distension [31]. In the original agar-based assay, nematodes were
fed on a lawn of pathogenic bacteria to establish the infection and
at an appropriate time point, worm survival was assayed by gently
probing the nematodes with a platinum loop to determine whether
they moved in response to touch. While this method might be
suitable for small scale screens, a less laborious approach utilizing
automation is necessary for high throughput, large scale screening.
A liquid-based screening assay was previously established for C.
elegans infected with Enterococcus faecalis [24,32]. However, adapta-
tions had to be made for the C. elegans – MRSA assay. Specifically,
in the C. elegans-E. faecalis HTS assay, larval stage L4 worms were
pre-infected with the pathogen prior to sorting. However, using
instrumentation to sort and dispense MRSA-infected worms is not
feasible because the robotic equipment cannot be efficiently
decontaminated after each use. To circumvent this problem, the
effectiveness of a co-infection assay, which involved sorting and
dispensing the worms in the assay wells and then inoculating the
wells with bacteria, was assessed (Fig. 1). Since a standard C.
elegans-S. aureus infection experiment on solid agar is carried out for
up to 5 days or longer [11], the liquid assay was carried out for a
similar duration. At the end of the assay, the wells were washed to
remove the bacteria and worms were stained with Sytox Orange,
which preferentially stains dead worms. The assay plates were
imaged with an ImageXpress microscope, capturing both trans-
mitted light and TRITC (535 nm excitation, 610 nm emission)
fluorescent images with a 2X objective. The use of a 2X objective
allows capturing the area of an entire well within one image. The
image data were analysed with CellProfiler image analysis software
to calculate worm survival based on fluorescence and transmitted
light images (Fig. 2). A similar liquid-based screening assay has
recently been described for a C. elegans-P. aeruginosa pathogenesis
model [33].
The liquid C. elegans–S. aureus assay was first optimized by testing
several concentrations of the MRSA strain MW2 with the starting
concentration ranging from an OD600 of 0.02 to 0.05. As a
negative control, the non-pathogenic E. coli strain OP50 was
added to the worms at the same concentration while keeping other
conditions unchanged. More than 90% of the worms treated with
OP50 survived after 5 days of co-infection for initial OD600,0.04,
but survival dropped to 73% when the starting OD600.0.04
(Fig. 3). It is possible that higher bacterial loads might kill worms
by suffocation, especially if the bacteria grow at a rate faster than
their consumption by the worms. Though C. elegans is able to
withstand low ambient oxygen levels, prolonged anoxia increases
mortality [34]. In contrast to worms exposed to E. coli, the survival
rate of worms exposed to S. aureus MW2 decreased to as low as 5%
with an initial OD600 of 0.05 (Fig. 3), confirming that S. aureus is
also capable of killing C. elegans in liquid media, similar to assays
Figure 3. Optimization of starting bacterial concentration used in the infection assay. Worms display a dose dependent susceptibility to
the S. aureus MW2 starting inoculum.
doi:10.1371/journal.pone.0089189.g003
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performed on solid agar plates. Given these results, an OD600 of
0.04, was deemed suitable for the infection assay as non-
pathogenic E. coli OP50 does not cause killing at this bacterial
concentration, whereas MW2 causes robust killing.
Evaluation of the Co-infection Assay
In order to determine the reproducibility and reliability of the
liquid infection assay, the Z’-factor, a standard measure of
robustness of high throughput assays, was determined. The Z’-
factor was calculated from CellProfiler-generated percentage
survival data from images of wells treated with DMSO (negative
control) and vancomycin (positive control) (Figure 4A). The Z’-
factor of the screening assay is 0.77 (Fig. 4B), which indicates a
very robust assay that is suitable for large scale screening.
Figure 4. C. elegans-MRSA liquid infection assay in 384-well plates. A) Assay plates were co-inoculated with nematodes, bacteria and either
DMSO (negative control) or vancomycin (10 mg/ml, positive control). The plates were incubated at 25uC for 5 days, washed to remove residual
bacteria and imaged. The tiled image was constructed from TRITC fluorescent images of each well from a 384-well plate. B) Worm survival was
significantly enhanced in wells treated with vancomycin.
doi:10.1371/journal.pone.0089189.g004
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Testing a Cell Wall Defective Strain in the Liquid Infection
Assay
In order to further confirm that the liquid killing assay behaves
similarly to the standard agar killing assay, we compared
nematode killing mediated by MW2 and MW2DtarO, a mutant
defective in wall teichoic acid (WTA) biosynthesis [35]. The
mutant strain defective in WTA biosynthesis is modestly attenu-
ated compared to a wild type strain in killing C. elegans on agar
plates [36]. In the liquid assay, worms infected with MW2DtarO
had a higher mean survival rate of 42.8% as compared to 9.6% for
worms infected with wild type MW2 (Fig. 5), demonstrating that a
previously tested mutant that was less virulent in an agar-based
assay is also less virulent in the liquid assay. Although the WTA
mutant strain is attenuated in both the agar and liquid-based
assays, the degree of attenuation of MW2DtarO is greater in liquid
than on agar. This suggests that the mechanism by which MW2
kills C. elegans in liquid may be different than on solid and that
WTA biosynthesis may play a greater role in liquid killing than in
the agar-based infection assay.
Identification of Antibiotic Compounds from the Screen
Using the optimized liquid screening assay, a pilot screen was
conducted with the Biomol 4 compound library consisting of 640
compounds representing several classes of drugs. These com-
pounds include 30 clinically used antibiotics with in vitro activity
against MRSA [37–62]. Based on the Z score threshold of 3, there
was a total of 40 hits, 25 of which were known antibiotics (Tables 1
and 2). Antibiotics such as clindamycin, lincomycin, novobiocin,
rifampicin and troleandomycin had Z scores greater than 20
suggesting that they are very strong hits. When the Z score
threshold was lowered to 2, two more antibiotics, enoxacin and
rufloxacin, were identified as hits. Both enoxacin and rufloxacin
have in vitro activity against MRSA [44,59], suggesting that the Z
score threshold of 2 may be appropriate in identifying hits for this
screen. In Figure 6, we present an example assay plate where wells
with a Z score greater than 2 have been highlighted in white
squares.
Interestingly, the Biomol 4 library includes three different
formulations of clindamycin, as a hydrochloride, phosphate and
Figure 5. A cell wall defective MRSA strain displays attenuated
killing of C. elegans in the liquid infection assay. Survival of
worms infected with either MW2 or MW2DtarO was assayed under the
same assay conditions. MW2DtarO was significantly attenuated in killing
compared to the wild type MW2 strain in the DMSO wells. Error bars
represent standard error.
doi:10.1371/journal.pone.0089189.g005
Figure 6. Sytox staining of assay plate. Tiled image of an example assay plate constructed from Sytox fluorescence images. White boxes indicate
compounds that enhanced survival of infected worms with Z score greater than 2, the red box indicates DMSO control wells, and the green box
indicates vancomycin positive control wells.
doi:10.1371/journal.pone.0089189.g006
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palmitate, but only clindamycin hydrochloride was identified as a
hit. Clindamycin hydrochloride is orally administered in capsules
whereas the palmitate version is present in oral suspensions and
clindamycin phosphate is topically administered. Among the three
versions, clindamycin hydrochloride probably had the highest
solubility, thereby accounting for its effectiveness in the assay.
Thus, the particular formulation of an antibiotic might affect its
activity in the assay.
The assay failed to detect three clinical antibiotics, gentamicin,
ciprofloxacin and trimethoprim. Trimethoprim is clinically effec-
tive on S. aureus only in combination with sulfamethoxazole [37].
Gentamicin and ciprofloxacin are mostly active against Gram-
negative bacteria and it is clinically recommended to use these
Figure 7. Closantel has a low in vitro MIC against VRSA. A) Structure of closantel. B) In vitro antimicrobial activity of closantel was compared
with vancomycin against the vancomycin resistant strain VRS1.
doi:10.1371/journal.pone.0089189.g007
Table 3. In vitro antimicrobial activity of closantel.
MIC (mg/ml)
Compound E. coli (OP50) B. subtilis (PY79) MRSA (MW2) VRSA (VRS1) E. faecalis (MMH594) E. faecium (E007)
Vancomycin .50 ,0.78 3.12 .50 6.25 1.56
Closantel .50 ,0.78 ,0.78 ,0.78 ,0.78 ,0.78
doi:10.1371/journal.pone.0089189.t003
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antibiotics in combination with vancomycin or rifampicin for
treating MRSA infections [63]. Also, we screened all compounds
at a relatively low concentration of 2.86 mg/ml, which might not
be sufficient for in vivo activity since it is likely that compounds may
degrade and worms may metabolize and inactivate some of the
compounds during the treatment period. Performing the assay at
higher compound concentrations might enable a higher rate of
detection but it might also increase the possibility that a potential
hit might be missed due to toxicity to worms. Ideally, the screen
would be performed at varying compound concentrations, which
is not practical when screening large chemical libraries.
Closantel is Active against Vancomycin Resistant
Staphylococci
One finding from this screen that drew our attention is that the
antihelminthic drug closantel (Fig. 7A) was able to prolong the
survival of nematodes in the liquid assay. Closantel is marketed as
a veterinary antihelminthic drug that is effective against several
species of nematodes [64,65]. Closantel is in the salicylinilide class
of drugs and although it has not been well studied, its anthelmintic
activity is thought to be as an uncoupler of oxidative phosphor-
ylation [66]. One might have expected that even if closantel does
have antibacterial activity, this compound would not have been
identified as a hit in our screen because of its toxicity to helminths.
However, closantel was identified as a hit with a relatively high Z
score of 7.16.
We tested the in vitro activity of closantel against other bacteria
such as E. coli, B. subtilis, E. faecalis and Enterococcus faecium and
found that indeed, it has a very low MIC with all Gram-positive
bacterial species tested (Table 3), similar to the findings in an
earlier study [67]. We found that this compound is also active
against another antibiotic-resistant S. aureus isolate, the VRSA
strain VRS1, with an MIC of at most 0.78 mg/ml (Table 3,
Fig. 7B). In comparison, the MIC of oxacillin or vancomycin for
the same strain was .256 mg/ml [15]. In order to test whether
closantel extends the lifespan of C. elegans exposed to MRSA by
inhibiting the growth of MRSA in the screening assay, we
measured the antibacterial activity of closantel on MRSA in the
assay wells in the presence of C. elegans. We measured the OD600 of
the wells with or without closantel at the start and end of an
infection assay. Unexpectedly, we found that the OD600 of MRSA
in wells containing closantel was on average similar to wells
without closantel at both the beginning of the assay (OD600,0.03)
and at the end of the assay (OD600,0.8) (data not shown). Our
data suggest that closantel is not affecting the growth of MRSA in
the assay despite the fact that closantel has a low MIC (,0.78 mg/
ml).
Intriguingly, Hlasta et al. [67] showed that closantel inhibits
two-component signaling (TCS) regulators in B. subtilis. TCS
regulators are conserved bacterial transcriptional regulators that
control a wide variety of processes in bacteria, such as virulence,
antibiotic resistance, and ability to adapt to the external
environment [68–70]. This suggests that the mechanism by which
closantel may promote longer lifespan in C. elegans exposed to
pathogen is by targeting master S. aureus transcriptional regulators.
Reasoning that TCS mutants corresponding to closantel targets
may be more susceptible to closantel, we tested the activity of
closantel on several S. aureus strains containing mutations in the
VraR-VraS TCS, a system important in promoting antibiotic
resistance, and GraR-GraS, a system important for virulence.
However, closantel inhibited the growth of the mutant strains to a
similar degree as the wild type strain (data not shown). Since it is
difficult to interpret these negative results, additional studies are
required to determine whether TCS of S. aureus is a potential target
of closantel. The TCS system, in general, may present an
attractive target for antimicrobial therapy as suggested by previous
studies [70–72].
In addition to the possibility that closantel targets bacterial
virulence, it is also possible that closantel could accumulate to low
levels in C. elegans cells and affect its biology, although it is clearly
not toxic to C. elegans at the effective dose of 2.86 mg/ml. In
contrast, the effective anthelmintic plasma concentrations of
closantel in sheep and cattle are ,50 mg/ml [73]. As stated
above, closantel is thought to act as an uncoupler of mitochondrial
oxidative phosphorylation, similar to other salicylanilides. It is
possible that at the relatively low concentration at which it cures C.
elegans of an MRSA infection, closantel may not completely disrupt
mitochondrial oxidative phosphorylation. In fact, the low concen-
trations of closantel may be having an entirely opposite effect.
Surprisingly, RNAi interference studies in C. elegans have shown
that slightly reduced function of mitochondrial oxidative phos-
phorylation machinery extends lifespan in C. elegans [74]. As
suggested by the RNAi experiments, it is possible that low
concentrations of closantel could be having a hormetic lifespan-
extending effect on the assay worms.
Concluding Remarks
In this study, a robust C. elegans-based liquid infection assay was
designed for testing both the anti-staphylococcal efficacy of
compounds and their toxicity to a host in a single step. The
ability of the assay to detect all of the clinically relevant antibiotics
from a chemical library lends credence to the potency of the assay.
Additionally, we report that the agent closantel identified in our
screen has significant activity against MRSA and VRSA. Closantel
is an attractive candidate for treatment of staphylococcal infections
and we are further investigating its mechanism of action and
clinical potential. Closantel is a prime example of the possibility of
‘‘repurposing’’ a drug already used in the clinic for other therapies.
The assays described here could advance drug discovery using
model organisms and decrease the need for mammalian testing.
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